Pharmafile Logo

flexible dosing

- PMLiVE

Regeneron’s Libtayo approved as flexible dosing schedule in EU

The flexible dosing schedule has been approved for patients with skin, lung and cervical cancer

- PMLiVE

Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss

Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss

- PMLiVE

AstraZeneca’s Trixeo gets EU approval for asthma maintenance treatment

Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history

- PMLiVE

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

The results from a global phase 3 trial show the longest survival data ever reported in this setting

- PMLiVE

Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA

Globally, around 150 to 200 out of every million people have myasthenia gravis

- PMLiVE

Regeneron agrees research collaboration with Parabilis Medicines

Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties

- PMLiVE

AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers

This is the first and only perioperative immunotherapy approved to treat early gastric cancers

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

Regeneron’s Libtayo receives EC approval for skin cancer

Phase 3 trial results showed the drug significantly improved disease-free survival

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links